2.3K(top 0.1%)
papers
106.1K(top 0.1%)
citations
138(top 0.1%)
h-index
289(top 0.1%)
g-index
2.4K
all documents
114.3K
doc citations
4.3K
citing journals

Top Articles

#TitleJournalYearCitations
1Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine20157,261
2Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine20173,865
3Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet, The20163,077
4Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine20122,474
5Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCNew England Journal of Medicine20182,150
6MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature20142,109
7Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine20132,019
8Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerNew England Journal of Medicine20201,513
9Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialLancet Oncology, The20191,467
10The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityNature20191,375
11Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine20121,201
12Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood20171,173
13Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialLancet Oncology, The20191,133
14Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine20211,129
15STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaCancer Discovery20181,108
16KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine20201,067
17Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology20151,035
18PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine2018997
19PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaNew England Journal of Medicine2014956
20Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet, The2011938
21Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine2018900
22Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialLancet, The2012856
23Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerJournal of Clinical Oncology2016755
24Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology2017750
25Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialLancet, The2016724
26Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyLancet, The2021711
27Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia2016685
28Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed TherapyJournal of Clinical Oncology2011647
29Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid TumorsJournal of Clinical Oncology2012635
30Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 StudyJournal of Clinical Oncology2018584
31Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyBreast Cancer Research and Treatment2018564
32Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaBlood2014562
33Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications2016550
34Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerAnnals of Oncology2018526
35Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyJournal of Clinical Oncology2016517
36MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast CancerClinical Cancer Research2017492
37Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialLancet Oncology, The2012487
38Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialLancet Oncology, The2012479
39CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerJournal of Clinical Oncology2018459
40Efficacy of Selpercatinib in RET-Altered Thyroid CancersNew England Journal of Medicine2020454
41Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialLancet Oncology, The2017453
42Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology2013451
43Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Annals of Oncology2014446
44Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncology, The2011444
45Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyLancet Oncology, The2017412
46Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaBlood2012396
47Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia2012395
48Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trialLancet, The2020393
49Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology2015392
50Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyJournal of Clinical Oncology2017384